ニュージャージーにおけるCOPDの臨床試験
ニュージャージー内の拠点で、COPDに関する7件の研究が参加者を募集しています。
ニュージャージー内の都市
公式研究テキスト（英語）
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Mullica Hill
- Research Site, Toms River
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Bioluminux Clinical Research - Hamilton, New Jersey- Site Number : 8400037, Hamilton
- Rutgers Institute For Infectious & Inflammatory Diseases (I3d)- Site Number : 8400093, Newark
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/10/01更新 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Sanmora Bespoke Clinical Research Solutions- Site Number : 8400144, East Orange
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07190209A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Millville
- Research Site, Sewell
- Research Site, Toms River
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06883305COPD Exacerbation Follow Up
- Cooper University Health Care, Cherry Hill
被験者募集中観察研究
40歳以上 · 全性別 · 2026/09/02更新 · NCT07118306Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Moorestown
- GSK Investigational Site, Sewell
被験者募集中第3相
40歳〜80歳 · 全性別 · 2026/04/09更新 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Inspira Medical Center, Mullica Hill
被験者募集中観察研究
50歳以上 · 全性別 · 2025/08/05更新 · NCT06122077ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。